Paper TrailKOREA
Why Korean and U.S. stocks moved, checked against filings

Nasdaq Fell 5.5%, and AppLovin Still Rose 31%: What the 8-K Says

With the S&P 500 down 4.36% on Nov. 5, AppLovin Corporation (APP) rose 31.04%, and Encore Capital Group, Inc. (ECPG) and ADMA Biologics, Inc. (ADMA) each gained more than 26%. All three filed earnings 8-Ks the day before.

Nasdaq Fell 5.5%, and AppLovin Still Rose 31%: What the 8-K Says

Basis: Nov. 6, 2026, 07:02 KST; prices are Nov. 5 regular-session closes.

Seoul — U.S. stocks sold off hard on Nov. 5. The S&P 500 fell 4.36%, the Nasdaq Composite fell 5.52% and the Russell 2000, the small-cap index, fell 4.45%. On that day AppLovin Corporation (APP) rose 31.04%, Encore Capital Group, Inc. (ECPG) rose 26.26% and ADMA Biologics, Inc. (ADMA) rose 26.05%. All three reported third-quarter results after the close on Nov. 4 and filed an 8-K (a current report to the SEC) with Item 2.02, results of operations. But the figures sit in attached press releases, and the strength of each rally differs.

At a glance

Stock Why it rose Nature Basis Heat What to check next
AppLovin (APP) +31.04% Strong Q3 results, a reported larger buyback Substantive, lasting Filing confirmed 2/4 overheated Buyback size in company documents, Schedule 14C
Encore (ECPG) +26.26% Q3 results, reported analyst upgrades Substantive, one-off Filing confirmed 0/4 normal Cash flow in the 10-Q, next-day trading value
ADMA (ADMA) +26.05% Reported Q3 beat Substantive, lasting Filing confirmed 0/4 normal Revenue growth in the 10-Q, whether after-hours gains hold

AppLovin rose 31% on a day the Nasdaq fell 5.5% (and the earnings filing exists)

AppLovin rose on its third-quarter results. In an 8-K filed Nov. 4 (Item 2.02), the company said it had issued a press release on results for the quarter ended Sept. 30. The 8-K itself has no figures; they are in Exhibit 99.1. Yahoo reported that third-quarter revenue rose 55%, and Benzinga said revenue and earnings per share beat estimates and fourth-quarter guidance topped forecasts. Yahoo and TradingNEWS cited a larger buyback in their headlines, but the 8-K text does not mention one. Barron's headlined the day's move as AppLovin surging while tech fell.

The stock closed at $356.10. After a 10.36% drop on Oct. 30 it gained three straight sessions, up 45.0% over two days (from the Nov. 3 close) and 39.7% over five (from the Oct. 29 close). Dollar volume was about $7.9 billion and market value about $119.6 billion. The same 8-K includes Item 5.07: holders with a majority of voting power approved, by written consent on Oct. 29, moving the company's incorporation from Delaware to Nevada. That is a governance matter separate from earnings.

Two of four overheating signals are on: the price is 33.6% above its 20-day average and volume was 5.1 times normal, while RSI is 74.6 and the five-day gain is 39.7%. Even so, the stock is 51.5% below its 52-week high and 13.1% below its 200-day line. It passes five of six earnings-quality checks (failed: debt ratio), with a P/E of 24.0 and revenue growth of 52.8%. Four Form 4 insider filings dated Nov. 2 also appear in the last seven days, but their transactions are not confirmed.

To judge whether this lasts, check whether the reported buyback size shows up in company documents such as the press release or 10-Q, and whether trading value stays elevated after this surge. The Schedule 14C on the Nevada move will also fill in the governance side.

Encore Capital Group hit a 52-week high, up 26% after earnings

Encore rose on its third-quarter results. The company filed an 8-K (Item 2.02) with a results press release on Nov. 4 and filed its 10-Q the same day. The 8-K text has no figures. TradingView ran an analysis headlined on U.S. debt purchasing and collections technology driving margin expansion, and Benzinga reported that Citizens raised its price target on strong earnings. The numbers themselves are not confirmed, but the market appears to have liked the report.

The stock closed at $126.17, up 26.26% to a 52-week high. It had hovered around $100 for weeks through Nov. 4, so nearly all of the move came in one day. Dollar volume was about $89.3 million and market value about $2.68 billion, far smaller than AppLovin. No overheating signals are on (0/4): the price is 23.3% above its 20-day average, volume was 3.3 times normal and RSI is 77.0. The stock is 49.9% above its 200-day line and passes four of six earnings-quality checks (failed: free cash flow, debt ratio), with a P/E of 9.6 and revenue growth of 11.3%.

Check the 10-Q for operating and free cash flow. Free cash flow is a failed item in that screen, so whether better earnings also show up as cash is the open question. Also watch whether trading value falls back to normal on the next session.

ADMA Biologics jumped from the after-hours session on earnings

ADMA Biologics, Inc. recent price and volume

ADMA also rose on its third-quarter results. It filed an 8-K (Item 2.02) on Nov. 4 with a results and business-update press release. The text is routine, so the figures come from news. Seeking Alpha said the stock jumped after a Q3 beat, and Benzinga reported a 28% after-hours gain. Mizuho raised its price target citing ASCENIV growth (Investing.com). The actual results figures are not confirmed.

The stock closed at $13.21, up 26.05%. It had fallen 5.67% the day before, so the two-day gain is 18.9% and the five-day gain 12.4%. Dollar volume was about $198.1 million and market value about $2.96 billion. No overheating signals are on (0/4): the price is 20.0% above its 20-day average, volume was 4.5 times normal and RSI is 70.2. It is 35.2% below its 52-week high and 21.9% above its 200-day line. It passes all six earnings-quality checks, though revenue growth is only 2.0%.

To judge whether this lasts, check the 10-Q to see whether revenue growth supports the price. The score is high but growth is low, so more expectation appears baked in. Also watch whether the price holds if next-day trading value falls below half of today's roughly $200 million.

Earlier stocks we covered, and what happened next

The table compares each article-day close with the Nov. 5 close. Nov. 5 was a day when the S&P 500 fell more than 4%, so market moves are mixed into the declines.

Stock Verdict then Article date Move
IDEXX Laboratories (IDXX) Earnings 11/3 -0.1%
Newell Brands (NWL) Earnings 11/3 -7.9%
Nextpower (NXT) Reported 11/3 +9.3%
Glaukos Corporation (GKOS) Earnings 10/30 -9.3%
ADT Inc. (ADT) Reported 10/30 +0.3%
Bausch Health Companies Inc. (BHC) Earnings 10/30 -10.7%
Axogen (AXGN) Filing 10/29 -1.0%
Genmab (GMAB) Reported 10/29 -7.9%

Of the four stocks that rose on earnings, three gave back the gains and IDEXX is about flat. The three that rose on reports were mixed: Nextpower +9.3%, ADT +0.3%, Genmab -7.9%. The three earnings-driven risers today deserve the same check in a few days.

FAQ

Why did AppLovin Corporation stock go up?

Strong Q3 results, a reported larger buyback. Evidence: Filing confirmed. What to check next: 2/4 overheated.

Why did Encore Capital Group, Inc. stock go up?

Q3 results, reported analyst upgrades. Evidence: Filing confirmed. What to check next: 0/4 normal.

Why did ADMA Biologics, Inc. stock go up?

Reported Q3 beat. Evidence: Filing confirmed. What to check next: 0/4 normal.

← Latest · Daily movers archive